Q2 FY27 revenue crosses Rs 500 crore, but cost pressures weaken margins

Management guided margin improvementManagement guided margin pressureOrder pipeline disclosedCFO laid out a debt-reduction roadmapInvestor Communications View source PDF Explain this filing

INDOCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹209.10

prior close

₹208.65

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.5%+2.9% vs market

Pharmaceuticals peers, median of 173sector-0.8%+1.2% vs sector

On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

+0.0

15m

-0.3

30m

-0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4-2.5+2.9-0.8+1.2

Next day

+3.3-1.1+4.4-0.8+4.1

+2.2-0.8+3.1-0.5+2.7

+2.0+1.3+0.7+0.3+1.7

+2.8+2.5+0.4+1.3+1.5

+2.8pendingpending+1.3+1.5

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q2 FY27 consolidated revenue rose 7.4% to Rs 506.9 crore and EBITDA margin was 9.2%. Standalone EBITDA margin fell from 12.4% to 9.2%. International formulations grew 12.1% and regulated markets 21.1%; domestic formulations fell to Rs 212.8 crore. Material costs and Rs 13 crore of additional freight pressured profit. Management targets high single-digit domestic and double-digit export growth, debt repayment and low capital spending.

Likely market impact

International growth supports sentiment, but domestic weakness, cost pressure and US plant regulatory uncertainty may limit near-term gains.